Hitoshi Ichikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hitoshi Ichikawa has a total of 329 co-authors. Here are the top co-authors by number of shared publications:
- Akihiko Yoshida
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
128 shared publications - Noboru Yamamoto
Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
119 shared publications - Akihiro Hirakawa
Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan
118 shared publications - Takafumi Koyama
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
118 shared publications - Hitomi Sumiyoshi Okuma
National Cancer Center Hospital, Tokyo, Japan
117 shared publications - Kan Yonemori
National Cancer Center Hospital, Tokyo, Japan
117 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Criteria for modifying treatment
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Criteria for modifying treatment
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Targeted sequencing analysis of cell-free DNA samples
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Targeted sequencing analysis of cell-free DNA samples
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Supplementary Dosing schedule in 11 patients
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Supplementary Dosing schedule in 11 patients
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Representativeness of study participant
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Representativeness of study participant
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Progression-free survival ratio
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Progression-free survival ratio
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment